South Atlantic Crossing (SACROSS) - Cruise No. M133: 15.12.2016-13.01.2017, Cape Town (South Africa)-Stanley (Falklands)

The cruise M133 SACROSS (South Atlantic Crossing) was a multidisciplinary ocean survey of the South Atlantic gyre roughly along 34.5° S. This transect is covered by the international SAMOC moored array and also the path of the internationally agreed AX18 XBT line. Most of the measurements were based on using underway methods including near-surface water sampling for the determination of SST, and SSS as well as shipboard ADCP current observations. Moreover, an underway CTD allowed to sample the upper 300-400 m every hour. Chemical analysis of surface waters as well as atmospheric parameter were of scientific interest to both compare different regions with each other but also to document long term trends. At the western and eastern boundary current regime full water column water mass properties were measured. Upper ocean 10-700m plankton assemblages allow improving the calibration of sediment proxies. Water samples for later lab-based biodiversity analysis were taken. A number of smaller student projects were carried out as part of a global ocean learning and capacity building effort. Finally, continuous swath bathymetry mapping was made, and a number of floats and drifters were launched in support of the global ocean observing system arrays. The cruise was very successful, all objectives were reached, and the measurements were carried out as planned

Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board

Background: Increasing knowledge of cancer biology and an expanding spectrum of molecularly targeted therapies provide the basis for precision oncology. Despite extensive gene diagnostics, previous reports indicate that less than 10% of patients benefit from this concept. Methods: We retrospectively analyzed all patients referred to our center’s Molecular Tumor Board (MTB) from 2018 to 2021. Molecular testing by next-generation sequencing (NGS) included a 67-gene panel for the detection of short-sequence variants and copy-number alterations, a 53- or 137-gene fusion panel and an ultra-low-coverage whole-genome sequencing for the detection of additional copy-number alterations outside the panel’s target regions. Immunohistochemistry for microsatellite instability and PD-L1 expression complemented NGS. Results: A total of 109 patients were referred to the MTB. In all, 78 patients received therapeutic proposals (70 based on NGS) and 33 were treated accordingly. Evaluable patients treated with MTB-recommended therapy (n = 30) had significantly longer progression-free survival than patients treated with other therapies (n = 17) (4.3 vs. 1.9 months, p = 0.0094). Seven patients treated with off-label regimens experienced major clinical benefits. Conclusion: The combined focused sequencing assays detected targetable alterations in the majority of patients. Patient benefits appeared to lie in the same range as with large-scale sequencing approaches